Admedus : Investor Presentation

WAYNE PATERSON

CEO

Presenting

A D M E D U S

I N V E S T O R P R E S E N T A T I O N M A Y 2 0 1 7

Disclaimer

This presentation is the property of Admedus Ltd ("Admedus"). No part of this presentation may be reproduced or transmitted in any form or by any means without direct permission in writing from Admedus. This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.

This presentation does not constitute an offer, solicitation or invitation in any, state or jurisdiction anywhere, or to any person to whom, such an offer or sale would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer, invitation or solicitation. Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to purchase or subscribe for securities in Admedus must be made solely on the basis of the information contained in the public domain and if necessary after seeking appropriate financial and legal advice.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Admedus and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liabilities arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it. Admedus' forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Admedus and its directors. Neither Admedus nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.

2

Admedus Today

• AHZ is a global medtech company with a focus on innovative medical devices

• Globally qualified and industry specific board of directors

  & management

   Cash = $14.4 (31/3/17)

   Market cap = $71M (24/5/17)

• Offices in Minneapolis, Australia, Zurich and Singapore

• Forecast $21M in revenue for FY16/17

  • Reported $17.2M at 9 month revenues last quarter

  • 3rd qtr sales of $4.9M

• Two main revenue streams

  • Infusion products distribution business

  • ADAPT® product portfolio

• Organic sales moving towards profitability

• Company de-risked and now starting to show revenue trends

• Blue sky opportunity with TAVR

• Multiple products in pipeline for future upside growth

3

Admedus Board

Wayne Paterson CEO

Ex- Merck Serono, Roche. 30 years in global healthcare including global and regional CEO roles as well as global marketing roles. Non-Executive Director of Cepheid (NASDAQ CHPD).

John Seaberg Chair

30 plus years medical device industry with a focus on the cardiovascular market. Served on board of Synovis Life Technologies until its sale to Baxter Inc. Current Executive VP of Cedar Point Capital and Chairman of Medicom Health interactive and Phraxis Inc.

Mathew Ratty Non Executive Director

Founder of MC Group, a globally focused venture fund, he has extensive capital, equity and debt markets experience and holds the role as Head of Investment at MC Group.

Simon Buckingham Non Executive Director

25 years of experience in the global Pharmaceutical/Biotech industry, having worked globally (Roche, Actelion) as well as in the US and Australia. NED on several public health care boards.

4